Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of June 29th – July 5th, 2020.

Without further ado, let’s get started.

* Yahoo Finance readers, please click here to view full article.

10. This U.S. Cannabis Stock Appears to Be Way Undervalued and May Actually Benefit From a Second Wave of the Pandemic

With That in Mind, Investors Should Be Paying Close Attention to This Newly Public Company, Which, Based on Projected Earnings, Appears to Be Way Undervalued Compared to its Peers

The pandemic first hit the U.S. earlier this year. The cannabis industry was deemed as essential and legal sales nationwide soared. With a possible second wave of the virus underway, investors should look at companies such as Red White & Bloom TDRYD, which controls a dominant 22% share of the Michigan market and compared to its multi-state operator (MSO) peers, is trading at an extremely attractive valuation.

READ FULL RWB ARTICLE

9. Patents for Psychedelics: “We Have the Potential to All Be Winners if We Do This Right”

In the Model of Startups Looking to Grow, Those Discoveries, That Intellectual Property, Can Make or Break a Company

Consider: In April, MindMed MMEDF, working with the University Hospital Basel’s Laboratory, in Basel, Switzerland in a deal to support clinical trials and secure exclusive patent rights, discovered and filed a patent in the U.S. preserving all worldwide rights for a neutralizer technology that can shorten or even stop the hallucinogenic effects of LSD in a therapy session.

READ FULL PSYCHEDELICS PATENTS ARTICLE

8. Cronos Group: Raymond James Sees US$4.10/Share Valuation Just for Ginkgos Partnership

Raymond James Has Created a Valuation Method Specific to Cannabinoid Biosynthesis

Raymond James recently upgraded Cronos Group CRON to an Outperform 2 rating as well as almost doubling their price target to C$13.52 / U$10. The justification behind this was that they believe Cronos’ partnership with Ginkgo Bioworks currently adds $1.54 billion or US$4.10 a share in value.

READ FULL CRONOS GROUP ARTICLE

7. Curaleaf Unveils Nationwide Expansion Plans for Select Brand

Select Products Will be Available in New Markets Including Maine, Massachusetts, Ohio and Florida This Summer

Curaleaf CURLF announced the continued expansion of its line of Select brand into new markets including Maine, Massachusetts, Ohio and Florida between now and August 2020.

READ FULL CURALEAF ARTICLE

6. Health Canada: ‘Any Celebrity Affiliation with Cannabis Has Potential to be Non-Compliant’

The Warning Comes as Some Major Canadian Producers Continue Offering Brands Affiliated to Varying Degrees with Celebrities or Popular Fictional Characters

Last week, Organigram OGI announced it was making adjustments to the Trailer Park Buds brand after discussions with the regulator. Other Canadian licensed producers (LPs) with celebrity ties include Canopy Growth CGC (Snoop Dogg’s Leafs by Snoop and Seth Rogen‘s Houseplant brand), Tilray TLRY (Marley Natural-branded vape cartridges) and Supreme Cannabis SPRWF (Wiz Khalifa’s Khalifa Kush).

READ FULL HEALTH CANADA ARTICLE

5. Better Cannabis Stock: Aphria vs. Canopy Growth

Which of These Struggling Pot Stocks Should You Buy?

Today, I’ll look at two of the top Pot Stocks in the industry — Aphria APHA and Canopy Growth CGC — and assess which of these leading cannabis producers is the better stock to hold in your portfolio.

READ FULL APHA VS WEED ARTICLE

4. Can Cannabis 2.0 Products Boost Canopy Growth and Organigram in 2020?

Will the Potential of Cannabis Derivatives Products Push These Two Marijuana Companies Towards Growth This Year?

While all marijuana companies ramped up production to grab the opportunities of this new market, Canopy Growth CGC and Organigram OGI have focused on providing the most innovative products to consumers.

READ FULL CANNABIS 2.0 ARTICLE

3. Psychedelics Outlook: A New Industry Emerges

Heading Into the Second Half of the Year, Industry Experts and Advocates Are Considering the Current Psychedelics Outlook as the Market Continues to Grow

The idea of investing in Psychedelics has captured the attention of the market, but what’s next for this exciting new segment?

READ FULL PSYCHEDELICS INVESTING ARTICLE

2. The 3 Marijuana Stocks You’ll Want to Own for the Second Half of 2020

These Cannabis Stocks Offer a Budding Opportunity in a High-Growth, But Still Relatively Nascent, Industry

While all “next big thing” industries need time to mature (and cannabis is no different), the following three Marijuana Stocks are the names you’ll want to own for the second half of 2020: Green Thumb GTBIF, Innovative Industrial Properties IIPR and Scotts Miracle-Gro SMG.

READ FULL MARIJUANA STOCKS ARTICLE

1. Revive Therapeutics Announces Submission of IND with FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

Once the FDA Allows the IND to Go Into Effect, Revive Will Initiate a Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19 in Q3 2020

Revive Therapeutics RVVTF announced it has submitted today its Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (FDA) for a Phase 3 confirmatory study for Bucillamine as a potential treatment in COVID-19.

READ FULL REVIVE THERAPEUTICS ARTICLE

Photo by Matteo Paganelli on Unsplash